DEF: NexGel 2026 Proxy: Reincorporation and Capital Raise

NexGel, Inc. seeks stockholder approval for reincorporation to Nevada, a significant increase in authorized shares, and a discretionary reverse stock split.

Summary

• The company is holding its 2026 Annual Meeting on July 10, 2026.
• Key proposals include the election of seven directors and the ratification of Turner, Stone & Company, L.L.P. as auditors.
• Proposal 2 seeks approval to issue shares exceeding 19.99% of outstanding stock related to April and May 2026 private placements of convertible notes and warrants.
• Proposal 3 proposes reincorporating from Delaware to Nevada to reduce franchise taxes and gain operational flexibility.
• Proposals 4 and 5 serve as Delaware-law fallbacks for increasing authorized shares to 100,000,000 and implementing a 1-for-2 to 1-for-10 reverse stock split if the Nevada reincorporation fails.
• As of June 3, 2026, there were 9,225,242 shares of common stock issued and outstanding.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a defensive filing reflecting significant financial pressure, characterized by heavy dilution risks and the need for emergency capital and regulatory compliance measures.

Positives

• Reincorporation to Nevada is expected to reduce annual franchise taxes and filing fees by approximately $15,000.
• Elimination of supermajority voting requirements for charter and bylaw amendments under the proposed Nevada structure.
• Extension of exculpation protections to officers under Nevada law, which may assist in talent retention.
• The company successfully raised capital through private placements in April and May 2026 to support working capital and business development.

Negatives

• Significant potential for dilution due to the conversion of notes and exercise of warrants, with no floor on the conversion price.
• The company currently faces a Nasdaq minimum bid price deficiency, necessitating a potential reverse stock split.
• The company has a shortfall of authorized shares, requiring an increase to meet contractual obligations.
• Nevada law may provide fewer rights and protections to stockholders compared to Delaware law, including higher thresholds for removing directors.

Risks

• Potential for substantial and unlimited dilution if the stock price declines, as conversion prices are subject to downward resets and full-ratchet anti-dilution adjustments.
• Risk of delisting from Nasdaq if the minimum bid price requirement is not met by October 19, 2026.
• Potential events of default under convertible notes if the company fails to reserve sufficient authorized shares.
• The variable rate transaction restriction in the financing agreements limits future capital-raising alternatives.

Future Outlook

The company intends to use proceeds from recent financings for working capital and business development. It is prioritizing regaining Nasdaq compliance and securing sufficient authorized shares to meet contractual obligations.

Management Comments

• The Board believes the reincorporation to Nevada will benefit the company through lower costs and greater operational flexibility.
• Management urges stockholders to vote in favor of all proposals to ensure the company can meet its financial obligations and maintain its Nasdaq listing.

Industry Context

StockSavvy.ai notes that NexGel is utilizing common defensive and capital-raising maneuvers typical for small-cap biotech/medical device firms facing liquidity constraints and Nasdaq compliance issues.

Comparison to Industry Standards

• The use of convertible notes with full-ratchet anti-dilution features is a high-cost financing method often seen in distressed small-cap companies.
• Reincorporation to Nevada is a common strategy for small-cap companies seeking to reduce administrative costs and benefit from more management-friendly corporate governance statutes.
• The proposed reverse stock split ratio (1-for-2 to 1-for-10) is standard for companies attempting to regain compliance with Nasdaq's $1.00 minimum bid price rule.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Sequence LifeScience, Inc. (affiliated with director Brian J. Kieser) participated in the April and May 2026 financings.
• Directors Adam Levy, Scott R. Henry, and Brian J. Kieser participated in the April and May 2026 financings on the same terms as unaffiliated investors.

Stakeholder Impact

• Existing shareholders face significant potential dilution from the conversion of notes and exercise of warrants.
• The reverse stock split will reduce the number of outstanding shares but will not change the proportionate equity interest of stockholders.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on July 10, 2026.
• File necessary documents with the Secretary of State of Nevada if Proposal 3 is approved.
• Monitor Nasdaq compliance status and potentially implement a reverse stock split if necessary.

Key Dates

Recommendation

The company is in a precarious financial position, relying on dilutive convertible debt to maintain operations and facing a Nasdaq delisting threat. While the reincorporation and share increase are necessary for survival, the extreme dilution risk makes the stock highly speculative.

Keywords

NexGel, NXGL, Proxy Statement, Reincorporation, Reverse Stock Split, Convertible Notes, Nasdaq Listing, Capital Raise